Search hospitals > North Dakota > Fargo
Sanford Medical Center Fargo
Claim this profileFargo, North Dakota 58104
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Lung Cancer
Conducts research for Recurrence
151 reported clinical trials
11 medical researchers
Summary
Sanford Medical Center Fargo is a medical facility located in Fargo, North Dakota. This center is recognized for care of Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Lung Cancer, Recurrence and other specialties. Sanford Medical Center Fargo is involved with conducting 151 clinical trials across 272 conditions. There are 11 research doctors associated with this hospital, such as Preston D. Steen, Daniel Almquist, Maria Bell, MD, and Lindsey Hines, MD.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderStage IV
ER positive
HER2 positive
Top PIs
Preston D. SteenSanford Roger Maris Cancer Center4 years of reported clinical research
Expert in Cancer
Expert in Lung Cancer
113 reported clinical trials
192 drugs studied
Daniel AlmquistSanford USD Medical Center - Sioux Falls4 years of reported clinical research
Expert in Cancer
Expert in Breast Cancer
84 reported clinical trials
141 drugs studied
Maria Bell, MDSanford Cancer Center Oncology Clinic8 years of reported clinical research
Studies Ovarian Cancer
Studies Ovarian Tumors
14 reported clinical trials
32 drugs studied
Lindsey Hines, MDSanford Health3 years of reported clinical research
Studies Acute Pain
Studies Depression
3 reported clinical trials
3 drugs studied
Clinical Trials running at Sanford Medical Center Fargo
Breast Cancer
Lung Cancer
Cancer
Gastric Cancer
Bladder Cancer
Esophageal Cancer
Anal Cancer
Esophageal Adenocarcinoma
Multiple Myeloma
Urothelial Carcinoma
Shorter Chemo-Immunotherapy Without Anthracyclines
for Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Support Program
for Breast Cancer
This phase III trial compares an additional support program (text message reminders and/or telephone-based counseling) with usual care in making sure breast cancer patients take their endocrine therapy medication as prescribed (medication adherence). Medication adherence is how well patients take the medication as prescribed by their doctors, and good medical adherence is when patients take medications correctly. Poor medication adherence has been shown to be a serious barrier to effective treatment for hormone receptor positive breast cancer patients. Adding text message reminders and/or telephone-based counseling to usual care may increase the number of days that patients take their endocrine therapy medication as prescribed.
Recruiting2 awards Phase 34 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Sanford Medical Center Fargo?
Sanford Medical Center Fargo is a medical facility located in Fargo, North Dakota. This center is recognized for care of Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Lung Cancer, Recurrence and other specialties. Sanford Medical Center Fargo is involved with conducting 151 clinical trials across 272 conditions. There are 11 research doctors associated with this hospital, such as Preston D. Steen, Daniel Almquist, Maria Bell, MD, and Lindsey Hines, MD.